MD854Z - Metodă de tratament al cancerului cervical local avansat de stadiul II-III - Google Patents
Metodă de tratament al cancerului cervical local avansat de stadiul II-III Download PDFInfo
- Publication number
- MD854Z MD854Z MDS20140049A MDS20140049A MD854Z MD 854 Z MD854 Z MD 854Z MD S20140049 A MDS20140049 A MD S20140049A MD S20140049 A MDS20140049 A MD S20140049A MD 854 Z MD854 Z MD 854Z
- Authority
- MD
- Moldova
- Prior art keywords
- treatment
- radiotherapy
- locally advanced
- patients
- cervical cancer
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 claims abstract description 40
- 238000001959 radiotherapy Methods 0.000 claims abstract description 25
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 10
- 229960004316 cisplatin Drugs 0.000 claims abstract description 10
- 235000016425 Arthrospira platensis Nutrition 0.000 claims abstract description 9
- 240000002900 Arthrospira platensis Species 0.000 claims abstract description 9
- 239000013543 active substance Substances 0.000 claims abstract description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 23
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 23
- 201000010881 cervical cancer Diseases 0.000 claims description 23
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000000771 oncological effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 238000002512 chemotherapy Methods 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 238000011835 investigation Methods 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 108010024636 Glutathione Proteins 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 206010037601 Pyelonephritis chronic Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000006368 chronic pyelonephritis Diseases 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000003724 spirulina extract Nutrition 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000005741 malignant process Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000005195 poor health Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000014393 valine Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140049A MD854Z (ro) | 2014-04-14 | 2014-04-14 | Metodă de tratament al cancerului cervical local avansat de stadiul II-III |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20140049A MD854Z (ro) | 2014-04-14 | 2014-04-14 | Metodă de tratament al cancerului cervical local avansat de stadiul II-III |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MD854Y MD854Y (mo) | 2014-12-31 |
| MD854Z true MD854Z (ro) | 2015-08-31 |
Family
ID=52211088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20140049A MD854Z (ro) | 2014-04-14 | 2014-04-14 | Metodă de tratament al cancerului cervical local avansat de stadiul II-III |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD854Z (mo) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD2544G2 (ro) * | 2004-05-14 | 2005-04-30 | Андрей ДОРУК | Metodă combinată de tratament a tumorilor maligne local răspândite ale capului şi gâtului |
| MD2543G2 (ro) * | 2004-05-14 | 2005-04-30 | Андрей ДОРУК | Metodă de tratament a tumorilor maligne local răspândite |
| MD2601G2 (ro) * | 2004-05-14 | 2005-07-31 | Андрей ДОРУК | Metodă combinata de tratament a tumorilor maligne local răspândite |
| MD3204G2 (ro) * | 2005-12-29 | 2007-07-31 | Валентина ДАРИЙ | Metodă de tratament preoperator al cancerului laringian |
-
2014
- 2014-04-14 MD MDS20140049A patent/MD854Z/ro not_active IP Right Cessation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD2544G2 (ro) * | 2004-05-14 | 2005-04-30 | Андрей ДОРУК | Metodă combinată de tratament a tumorilor maligne local răspândite ale capului şi gâtului |
| MD2543G2 (ro) * | 2004-05-14 | 2005-04-30 | Андрей ДОРУК | Metodă de tratament a tumorilor maligne local răspândite |
| MD2601G2 (ro) * | 2004-05-14 | 2005-07-31 | Андрей ДОРУК | Metodă combinata de tratament a tumorilor maligne local răspândite |
| MD3204G2 (ro) * | 2005-12-29 | 2007-07-31 | Валентина ДАРИЙ | Metodă de tratament preoperator al cancerului laringian |
Non-Patent Citations (1)
| Title |
|---|
| Бойко А.В. и др. Использование радиомодификации для расширения показаний к радикальному лучевому лечению больных с местно-распространенными формами рака шейки матки. Казанский медицинский журнал. Том LXXXI, №4, 2000, p.287-289 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MD854Y (mo) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12350298B2 (en) | Microbiome related immunotherapies | |
| Xue et al. | Astaxanthin attenuates total body irradiation-induced hematopoietic system injury in mice via inhibition of oxidative stress and apoptosis | |
| Mo et al. | ROS scavenging nanozyme modulates immunosuppression for sensitized cancer immunotherapy | |
| WO2010009735A2 (en) | Combinatorial analysis and repair | |
| JP6488276B2 (ja) | 天然化合物及び／又は食事を用いる癌の調節 | |
| US20200323820A1 (en) | Materials and methods for inhibiting tumor growth | |
| EP4226930A1 (en) | Composition for preventing or treating cancer comprising bifidobacterium longum rapo (kctc13773bp) | |
| Liu et al. | Low-dose naltrexone inhibits the epithelial-mesenchymal transition of cervical cancer cells in vitro and effects indirectly on tumor-associated macrophages in vivo | |
| Yan et al. | Ligilactobacillus salivarius CCFM 1266 modulates gut microbiota and GPR109a-mediated immune suppression to attenuate immune checkpoint blockade-induced colitis | |
| Haiyan et al. | Growth of breast cancer cells inhibited by bromelains extracted from the different tissues of pineapple | |
| JP2022533723A (ja) | ヒ素の治療効果を増強するための金属イオンの使用 | |
| CN116726021A (zh) | 一种drp1抑制剂和铁死亡诱导剂联合用药物及其抗肿瘤的用途 | |
| Jia et al. | An injectable biomimetic hydrogel adapting brain tissue mechanical strength for postoperative treatment of glioblastoma without anti-tumor drugs participation | |
| CN107557333A (zh) | 一种用于细胞治疗的新抗原呈递细胞的制备方法 | |
| MD854Z (ro) | Metodă de tratament al cancerului cervical local avansat de stadiul II-III | |
| Dodge et al. | Effects of donor vitamin A deficiency and pharmacologic modulation of donor T cell retinoic acid pathway on the severity of experimental graft-versus-host disease | |
| JP2019508388A (ja) | 骨髄抑制を治療するための薬物の製造におけるフラーレン／金属フラーレンの使用 | |
| CN117298043A (zh) | 一种纳米水凝胶前驱体及其制备方法与应用 | |
| CN105168241B (zh) | 硫化氢在提高抗肿瘤药物抑瘤率中的应用 | |
| CN115554317A (zh) | 一种用于治疗肿瘤的药物组合物、试剂盒及其应用 | |
| TWI722492B (zh) | 含蓮蓬萃取物之組合物及其用於治療頭頸癌症之用途 | |
| Niu et al. | Manganese-based nanozymes as broad-spectrum antioxidants against cisplatin-induced skeletal muscle atrophy | |
| EP1881838B1 (en) | Antitumor agent on the base of bcg vaccine, method for its preparation and its use | |
| TWI690327B (zh) | 西瑞香素於預防組織或器官移植排斥或是移植物抗宿主疾病之用途 | |
| US20150329824A1 (en) | Z cells activated by zinc finger-like protein and uses thereof in cancer treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG9Y | Short term patent issued | ||
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |